Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk

American Journal of Cardiology

Volumn 91, Issue 10, 2003, Pages 1173-1177

  Sniderman, Allan D ^b   St Pierre, Annie C ^b   Cantin, Bernard ^b   Dagenais, Gilles R ^b   Després, Jean Pierre ^b   Lamarche, Benoît ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; POPULATION DISTRIBUTION; PREDICTION; PRIORITY JOURNAL;

EID: 0038402528     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00262-5     Document Type: Article

References (12)

1. Sniderman A.D., Furberg C.D., Keech A., Roeters van Lennep J.E., Frolich J.J., Jungner I., Walldius G. Apoproteins versus lipids as indices of coronary risk and as targets for statin therapy analysis of the evidence . Lancet. 36:2003;777-780.
2. Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
3. Dagenais G.R., Robitaille N.M., Lupien P.J., Christen A., Gingras S., Moorjani S., Meyer F., Rochon J. First coronary heart disease event rates in relation to major risk factors Québec cardiovascular study . Can J Cardiol. 6:1990;274-280.
4. Lamarche B., Després J.P., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Québec Cardiovascular Study). Am J Cardiol. 75:1995;1189-1195.
5. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
6. Lamarche B., Moorjani S., Lupien P.J., Cantin B., Bernard P.M., Dagenais G.R., Després J.P. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec Cardiovascular Study. Circulation. 94:1996;273-278.
7. Lamarche B., St Pierre A.C., Ruel I.L., Cantin B., Dagenais G.R., Despres J.P. A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can J Cardiol. 17:2001;859-865.
8. Landis J.R., Koch G.G. The measurement of observer agreement for categorical data. Biometrics. 33:1977;159-174.
9. Ballantyne C.M., Andrews T.C., Hsia J.A., Kramer J.H., Shear C. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels . Am J Cardiol. 88:2001;265-269.
10. Vega G.L., Grundy S.M. Does measurement of apolipoprotein have a place in cholesterol management? Arterioscler Thromb Vasc Biol. 10:1990;668-671.
11. Sniderman A.D., Cianflone K. Lipids and vascular disease what we do and do not know . Clin Chim Acta. 286:1999;7-22.
12. Illingworth D.R., Stein E.A., Mitchel Y.B., Dujovne C.A., Frost P.H., Knopp R.H., Tun P., Zupkis R.V., Greguski R.A. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med. 154:1994;1586-1595.